Preparation method of amine-substituted phenanthridine compound
By using the mild reaction of compound (I) with basic salts and amines in organic solvents, the problem of dependence on noble metal catalysts in the prior art is solved, and the efficient synthesis of amine-substituted phenanthridine compounds is achieved, which is applicable to the modification of a variety of drug molecules.
Patent Information
- Application Number
- CN202510921193.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-04
- Publication Date
- 2025-11-28
AI Technical Summary
Existing nitrogen heterocyclic amination methods rely on noble metal catalysts, require high-temperature conditions and stoichiometric base additives, and are difficult to avoid affecting the active structure. They are also not suitable for natural products or drug molecules containing pyrrole or indole structures.
The synthesis of amine-substituted phenanthridine compounds was achieved by reacting compound (I), a basic salt, and an amine compound in an organic solvent under mild conditions. Post-processing included extraction and column chromatography purification.
This method enables the synthesis of amine-substituted phenanthridine compounds with high yield, low cost, and wide applicability, avoiding the use of high temperature and precious metal catalysts, and is suitable for the modification of a variety of drug molecules.
Smart Images

Figure BDA0005483169010000011 
Figure BDA0005483169010000022 
Figure BDA0005483169010000033
Abstract
Description
TECHNICAL FIELD
[0001] The application relates to a preparation method of an amine-substituted phenanthridine compound and belongs to the technical field of medicines for nervous system diseases. BACKGROUND
[0002] The amination reaction of nitrogen heterocyclic compounds is an important and widely studied topic in organic synthetic chemistry. Such structures are widely present in drug molecules and natural products and have high application value in pharmaceutical chemistry and material science, such as quetiapine fumarate, loxapine, amoxapine and antitubercular factor.
[0003]
[0004] Traditional amination methods of nitrogen heterocyclic compounds mainly rely on pre-synthesized halogenated nitrogen heterocyclic precursors, and then a carbon-carbon or carbon-nitrogen bond is constructed through a transition metal-catalyzed cross-coupling reaction, such as CN101190902A, CN101198599A, CN105859653A, CN114181172A and CN120136813A. However, the nitrogen-containing substrate often causes passivation to the noble metal catalyst, and a carefully designed ligand is needed to maintain the optimal reaction conditions and catalytic efficiency, and often needs to be supplemented with high-temperature conditions and stoichiometric base additives. These are limited by the use of air-sensitive reagents, ligands or catalysts.
[0005] In addition, for some natural products or drug molecules containing pyrrole or indole structures, there are amide groups or ester groups and other relatively active structures, which are difficult to avoid affecting these relatively active structures while realizing the modification of the amine. Therefore, it is of great significance to develop a mild reaction to realize amine group-promoted phenanthridine synthesis. SUMMARY
[0006] Therefore, the application provides a preparation method of an amine-substituted phenanthridine compound, which has the advantages of good synthesis yield, wide application range, low cost and high practicality.
[0007] Specifically, the application is realized through the following scheme:
[0008] A preparation method of an amine-substituted phenanthridine compound, wherein compound (I), an alkaline salt and an amine compound are added to an organic solvent, and then reacted at 0-60 DEG C for 4-8 hours, and then the expanded rearrangement product amine-substituted phenanthridine compound is obtained through post-treatment,
[0009] The structural formula of the compound (I) is as follows: n=0 or 1, and OTf is trifluoromethylsulfonyloxy.
[0010] Further, as a preferred:
[0011] The basic salt is potassium tert-butoxide or potassium carbonate.
[0012] The amine compound is melatonin, D-amino acid oxidase inhibitor, fludioxonil, indazole, benzimidazole, benzomorpholine, carbazole and its substitutes, 2-[2-(1-piperazinyl)ethoxy]ethanol.
[0013] The organic solvent is N,N-dimethylformamide (DMF). At this time, the amount of the organic solvent added corresponding to 1 mmol of compound (I) is 10-15 mL.
[0014] The amine-substituted phenanthridine compound has any one of the following structures:
[0015]
[0016] The molar ratio of compound (I), the basic salt and the amine compound is 1:1-2:1-2. Preferably, it is 1:1.8-2:1.2-2.
[0017] The post-treatment refers to that the reaction product is extracted, mixed with silica gel, and then purified by column chromatography to obtain the corresponding deuterated aromatic compound. The column chromatography purification is a common technical means in the art.
[0018] When the structural formula of compound (I) is (9-thioxanthone oxime ester), the corresponding basic salt is potassium carbonate, the amine compound is 2-[2-(1-piperazinyl)ethoxy]ethanol, and the amine-substituted phenanthridine compound is quetiapine At this time, the reaction process is preferably 0°C for 4 hours.
[0019] The reaction formula of the above preparation process is as follows:
[0020]
[0021] The obtained product quetiapine can be used to synthesize fumaric acid quetiapine: the amine-substituted phenanthridine compound and fumaric acid are added to an organic solvent, and after reflux heating reaction at 80°C, the modified fumaric acid quetiapine is obtained
[0022] Preferably:
[0023] The obtained product after reflux heating is recrystallized with petroleum ether PE and methanol to obtain the product.
[0024] The molar ratio of quetiapine and fumaric acid satisfies quetiapine:fumaric acid = 1:0.6.
[0025] The organic solvent is ethanol. At this time, the amount of the organic solvent added corresponding to 1 mmol of quetiapine is 10-15 mL.
[0026] When the compound (I) has the structural formula of (9-fluorene ketoxime ester), the corresponding basic salt is potassium tert-butoxide, the amine compound is melatonin, D-amino acid oxidase inhibitor, fludioxonil, indazole, benzimidazole, benzomorpholine or carbazole and its substitutes. In this case, the reaction process is preferably divided into two stages: first, react at 0°C for 20 minutes, then raise the temperature to 60°C for 4.5 hours.
[0027] When the amine compound is melatonin, the reaction of the above preparation process is expressed as follows:
[0028]
[0029] When the amine compound is D-amino acid oxidase inhibitor, the reaction of the above preparation process is expressed as follows:
[0030]
[0031] When the amine compound is fludioxonil, the reaction of the above preparation process is expressed as follows:
[0032]
[0033] When the amine compound is indazole, the reaction of the above preparation process is expressed as follows:
[0034]
[0035] When the amine compound is benzimidazole, the reaction of the above preparation process is expressed as follows:
[0036]
[0037] When the amine compound is benzomorpholine, the reaction of the above preparation process is expressed as follows:
[0038]
[0039] When the amine compound is carbazole and its substitutes, the reaction of the above preparation process is expressed as follows:
[0040] R is H (in this case, the amine compound is carbazole), phenyl (in this case, the amine compound is 3,6-diphenyl-9-H-carbazole), halogen (F, Cl, Br, I), methyl, ethyl, propyl, butyl, methoxy, thiomethyl, heterocyclic aromatic group (such as furanyl, thienyl, benzofuranyl, benzothienyl, etc., acetamide, benzamide, etc.
[0041] In the preparation of the above-mentioned amine-substituted phenanthridine compounds, compound (I) is inexpensive and easy to synthesize as a reaction substrate. Amine compounds are generally commercially available products, readily accessible from the market. The phenanthridine or dibenzothiazoline unit in the modified amine compound can be obtained through conversion with 9-fluorenone oxime ester or 9-thioxanone oxime ester. The reaction can be completely converted using ordinary heating. No light or microwave conditions are required during the reaction, making the conditions mild and easy to implement. The preparation steps are simple, the reaction conditions are mild, and the process is convenient for operation and application. This method enables the efficient modification and conversion of amine compounds into corresponding amine-substituted phenanthridine compounds (including quetiapine) for efficient synthesis.
[0042] Compared with the prior art, the beneficial effects of the present invention are reflected in the following: the starting materials and alkali salts of the preparation method are inexpensive and readily available, the reaction conditions are simple and mild, the steps are simple, and it is easy to operate and apply later. The reaction substrates are highly designable, the substrate functional groups have a wide tolerance range, and different amine compounds can be designed and modified and drug molecules synthesized according to actual needs, making it highly practical. Detailed Implementation
[0043] To make the technical problems, technical solutions, and beneficial effects to be solved by this application clearer, the technical solutions of this application will be further described in detail below with reference to specific examples in the embodiments of this application. It should be understood that the specific embodiments described herein are only used to explain this application and are not intended to limit the technical solutions of this application. Based on the embodiments in this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.
[0044] Example 1
[0045] The synthesis process of the amine-substituted phenanthridine compound in this embodiment is as follows:
[0046] Raw material preparation: 0.2 mmol of 9-thioxanone oxime ester, 2 equivalents of potassium carbonate, 2 equivalents of 2-[2-(1-piperazinyl)ethoxy]ethanol, and 2 mL of N,N-dimethylformamide (DMF) as solvent.
[0047] Reaction procedure: 9-Thioxanone oxime ester, potassium carbonate, and 2-[2-(1-piperazinyl)ethoxy]ethanol were added to a 35 mL Schlenk tube as solvent. After reacting at 0°C for 4 hours, the mixture was extracted with ethyl acetate, washed with water to remove DMF, mixed with silica gel, and purified by column chromatography to obtain the corresponding deuterated aromatic compound. Yield: 70%.
[0048] The structural formula of 9-thioxanone oxime ester is: OTf stands for trifluoromethanesulfonyloxy.
[0049] The structural formula of 2-[2-(1-piperazinyl)ethoxy]ethanol is:
[0050] The structural formula of quetiapine, an amine-substituted phenanthridine compound, is as follows:
[0051] The reaction formula is as follows:
[0052]
[0053] The obtained quetiapine was converted into quetiapine fumarate.
[0054] Raw material preparation: Quetiapine added at 0.14 mmol, 0.6 equivalent fumaric acid, and 1.4 mL ethanol as solvent.
[0055] Reaction procedure: Quetiapine and fumaric acid were added to a solvent in a 35 mL Schlenk tube and refluxed at 80 °C. After reacting for 3 hours, the mixture was evaporated to dryness and recrystallized from petroleum ether and methanol to obtain the target product. Yield: 89%.
[0056] The structural formula of the product, quetiapine fumarate, is:
[0057] Nuclear magnetic resonance imaging of quetiapine fumarate (NMR) 1 H NMR, 13 (C NMR) detection:
[0058] 1 H NMR (400MHz, Methanol-d4) δ8.00 (dd, J=7.8, 1.6Hz, 1H), 7.55 (dd, J=8.1, 1.3Hz, 1H), 7.4 6-7.37(m,2H),7.33(m,J=7.7,1.6Hz,1H),7.21(m,J=15.1,7.5,1.3Hz,2H),6.85(dd,J=8 .1,1.1Hz,1H),4.63-4.45(m,2H),3.90-3.78(m,2H),3.74(t,J=4.9Hz,2H),3.38(s,1H), 3.34(q,J=1.7Hz,1H),3.15(t,J=5.3Hz,4H),2.90(t,J=5.0Hz,4H),2.80(t,J=4.9Hz,2H).
[0059] 13C NMR(101MHz,Methanol-d4)δ167.63,166.50,143.27,141.66,136.12,134.12,132.31,130.67,12 9.77,128.66,128.30,127.75,126.06,125.30,124.57,68.78,67.93,63.63,56.85,49.75,42.86.
[0060] Example 2
[0061] The synthesis process of the amine-substituted phenanthridine compound in this embodiment is as follows:
[0062] Raw material preparation: 0.2 mmol of 9-fluorenone oxime ester, 1.8 equivalents of potassium tert-butoxide, 1.2 equivalents of melatonin (amine compound), and 2 mL of N,N-dimethylformamide (DMF) as solvent.
[0063] Reaction procedure: 9-fluorenone oxime ester, potassium tert-butoxide, and melatonin were added to a solvent in a 35 mL Schlenk tube. The reaction was carried out at 0°C for 20 minutes, then the temperature was increased to 60°C and the reaction was carried out for 4.5 hours. After the reaction was complete, the sample was extracted with ethyl acetate, washed with water to remove DMF, mixed with silica gel, and purified by column chromatography to obtain the corresponding deuterated aromatic compound. Yield: 94%.
[0064] The structural formula of 9-fluorenone oxime ester is: OTf stands for trifluoromethanesulfonyloxy.
[0065] The structural formula of melatonin is:
[0066] The structural formula of melatonin replacing phenanthridine is:
[0067] Nuclear magnetic resonance (NMR) was performed on the obtained melatonin-substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0068] 1H NMR(400MHz,Chloroform-d)δ8.23(d,J=7.6Hz,1H),7.79-7.73(m,1H),7.67-7.56(m,3H),7.41(m,J=11.8,7.5,1.2Hz,2H),7.23(s,1H) ,7.04(d,J=2.4Hz,1H),7.00(dd,J=8.9,2.4Hz,1H),6.23(s,1H),3.89(s,3H),3.61(q,J=6.4Hz,2H),2.96(t,J=6.6Hz,2H),1.86(s,3H).
[0069] 13 C NMR(101MHz,Chloroform-d)δ170.10,154.67,153.45,141.59,140.42,135.27,132.09,131.35,130.44,130.33,129.46 ,129.22,128.25,128.01,126.75,121.79,119.96,113.29,112.62,111.13,100.92,79.50,55.99,39.47,25.21,23.36.
[0070] Example 3
[0071] The setup in this embodiment is the same as in embodiment 2, except that:
[0072] The amine compound used is a D-amino acid oxidase inhibitor, and its structural formula is as follows:
[0073] The structural formula of the D-amino acid oxidase inhibitor replacing phenanthridine is:
[0074] Yield: 75%.
[0075] Nuclear magnetic resonance (NMR) analysis was performed on the obtained D-amino acid oxidase inhibitor substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0076] 1H NMR (400MHz, Chloroform-d) δ8.68(d,J=8.3Hz,1H),8.62(t,J=7.8Hz,2H),8.55(dd,J=8.3,1.4Hz,1H),8.18(dd,J=8. 2,1.4Hz,1H),8.11(dd,J=7.5,2.2Hz,1H),7.96(m,J=8.3,7.0,1.4Hz,1H),7.83(m,J=8.2,7.1,1.2Hz,1H),7.76-7.71 (m,2H),7.67(d,J=7.5Hz,1H),7.63(td,J=7.6,7.0,1.3Hz,1H),7.55(td,J=7.5,1.2Hz,1H),7.46(m,J=16.4,7.5,1.2 Hz,2H),7.40-7.32(m,3H),7.18(d,J=1.9Hz,2H),6.99(d,J=5.3Hz,2H),4.40(d,J=7.1Hz,3H),1.41(t,J=7.1Hz,6H).
[0077] 13 C NMR(101MHz,Chloroform-d)δ161.73,158.43,158.26,142.97,142.58,141.35, 140.94,135.59,135.03,132.28,131.40,131.25,130.64,129.90,129.44,129. 13,129.10,128.58,128.33,127.79,127.11,125.65,124.80,124.75,123.60,123.39,122.48,122.11,120.38,120.05,118.86,111.17,107.58,60.72,14.51.
[0078] Example 4
[0079] The setup in this embodiment is the same as in embodiment 2, except that:
[0080] The amine compound used is fludioxonil, and its structural formula is:
[0081] The structural formula of fludioxonil substituted with phenanthridine is:
[0082] Yield: 72%.
[0083] Nuclear magnetic resonance (NMR) analysis was performed on the obtained fludioxonil-substituted phenanthridine. 1 H NMR, 13C NMR, 19 F NMR detection:
[0084] 1 H NMR(400MHz,Chloroform-d)δ8.80(d,J=8.4Hz,1H),8.68(d,J=8.0Hz,1H),8.21(d,J=8.0Hz,1H),8.16(d,J=8 .3Hz,1H),8.03(s,1H),7.89(d,J=2.3Hz,1H),7.88-7.80(m,4H),7.25(t,J=8.1Hz,1H),7.08(d,J=8.0Hz,1H).
[0085] 13 C NMR(101MHz,Chloroform-d)δ148.48,143.99,142.46,140.18,135.59,134.10-128.82(t,J=266.6),132.07,131.01,130.10,12 9.85,128.52,128.28,125.50,124.37,124.27,123.51,123.03,122.29,121.67,120.87,119.37,115.99,115.92,108.40,93.74.
[0086] 19 F NMR(376MHz,Chloroform-d)δ-49.41.
[0087] Example 5
[0088] The setup in this embodiment is the same as in embodiment 2, except that:
[0089] The amine compound used is indazole, and its structural formula is:
[0090] The structural formula of indazole-substituted phenanthridine is:
[0091] Yield: 64%.
[0092] Nuclear magnetic resonance (NMR) was performed on the obtained indazole-substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0093] 1H NMR(400MHz,Chloroform-d)δ8.77(t,J=9.1Hz,2H),8.71-8.60(m,1H),8.42(s,1H),8.30-8.19(m,2H),7.99-7.89(m,2H ),7.82(m,J=8.3,7.0,1.4Hz,1H),7.76(tdd,J=7.0,2.8,1.3Hz,2H),7.57(m,J=8.4,7.0,1.2Hz,1H),7.46-7.32(m,1H).
[0094] 13 C NMR(101MHz,Chloroform-d)δ149.97,142.66,140.78,136.79,135.71,131.23,129.64,129.23,1 28.26,127.76,127.72,127.21,125.27,124.14,122.58,122.29,122.24,121.98,120.96,113.49.
[0095] Example 6
[0096] The setup in this embodiment is the same as in embodiment 2, except that:
[0097] The amine compound used is benzimidazole, and its structural formula is:
[0098] The structural formula of benzimidazole-substituted phenanthridine is:
[0099] Yield: 75%.
[0100] Nuclear magnetic resonance (NMR) was performed on the obtained benzimidazole-substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0101] 1 H NMR(400MHz,Chloroform-d)δ8.81(d,J=8.3Hz,1H),8.73-8.67(m,1H),8.52(d,J=1.3Hz,1H),8.29-8.16( m,1H),8.06-7.95(m,3H),7.92-7.77(m,2H),7.75-7.67(m,1H),7.51-7.39(m,2H),7.35(t,J=7.7Hz,1H).
[0102] 13C NMR(101MHz,Chloroform-d)δ147.64,143.84,143.22,143.04,135.45,134.55,131.96,130.13,1 29.68,128.22,128.06,126.16,124.38,124.01,123.22,122.87,122.31,121.96,120.71,112.03.
[0103] Example 7
[0104] The setup in this embodiment is the same as in embodiment 2, except that:
[0105] The amine compound used is benzomorpholine, and its structural formula is:
[0106] The structural formula of benzomorpholine-substituted phenanthridine is:
[0107] Yield: 72%.
[0108] Nuclear magnetic resonance (NMR) was performed on the obtained benzomorpholine-substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0109] 1 H NMR(400MHz,Chloroform-d)δ8.66(d,J=8.3Hz,1H),8.62-8.49(m,1H),8.27(d,J=8. 3Hz,1H),8.11-7.99(m,1H),7.85(m,J=8.3,6.9,1.3Hz,1H),7.80-7.68(m,1H),7.62( dt,J=15.6,8.0Hz,2H),6.98(dd,J=8.1,1.5Hz,1H),6.89-6.81(m,1H),6.61(td,J=7. 8,7.3,1.5Hz,1H),6.44(dd,J=8.2,1.5Hz,1H),4.77-4.33(m,2H),4.20-3.97(m,2H).
[0110] 13C NMR(101MHz,Chloroform-d)δ155.25,144.86,144.07,134.85,133.00,130.76,129.03,128.93,127. 53,127.17,125.98,123.37,122.73,122.64,122.05,121.57,120.29,117.95,116.85,66.44,46.45.
[0111] Example 8
[0112] The setup in this embodiment is the same as in embodiment 2, except that:
[0113] The amine compound used is carbazole, and its structural formula is:
[0114] The structural formula of carbazole-substituted phenanthridine is:
[0115] Yield: 72%.
[0116] Nuclear magnetic resonance (NMR) was performed on the obtained carbazole-substituted phenanthridine. 1 H NMR, 13 (C NMR) detection:
[0117] 1 H NMR(400MHz,Chloroform-d)δ8.83(d,J=8.4Hz,1H),8.76(d,J=7.8Hz,1H),8.27(t,J=8.7Hz,3H),7.96(t,J=7.7H z,1H),7.92-7.82(m,2H),7.79(d,J=8.3Hz,1H),7.59(t,J=7.6Hz,1H),7.47-7.34(m,4H),7.29(d,J=8.2Hz,2H).
[0118] 13 C NMR(101MHz,Chloroform-d)δ150.04,143.74,141.39,135.45,131.69,130.20,129.37,127.8 8,127.78,127.17,126.13,124.53,124.02,123.48,122.69,122.31,120.60,120.42,111.28.
[0119] As can be seen from the above examples, when the reaction is complete, amine compounds with different structures all exhibit certain reactivity. This demonstrates that the synthetic method of this application has good yield and reaction selectivity, and is applicable to a very wide range of substrates. This method can be conveniently applied to the late-stage modification of drug molecules. This synthetic method does not require transition metal catalysis or ligand assistance, directly converting 9-fluorenone oxime ester into an amine-substituted phenanthridine compound. It can be applied to the direct modification of drug molecules known to contain secondary amine structures, offering high practicality, low cost, and simple operation, and has extremely high application potential in the field of drug synthesis.
[0120] The above-described embodiments are merely illustrative of several feasible implementations of the present invention, and their descriptions are relatively specific and detailed. However, they should not be construed as limiting the scope of the present invention, nor are the embodiments intended to limit the scope of protection in the claims of the present invention. For those skilled in the art, various modifications and improvements can be made without departing from the concept of the present invention. All equivalent implementations or changes that do not depart from the present invention should be included in the technology of the present invention.
Claims
1. A method for preparing an amine-substituted phenanthridine compound, characterized in that: Compound (I), its basic salt, and an amine compound were added to an organic solvent and reacted at 0–60°C for 4–8 hours to obtain an amine-substituted phenanthridine compound. The structural formula of compound (I) is: n = 0 or 1, OTf is trifluoromethanesulfonyloxy.
2. The method for preparing an amine-substituted phenanthridine compound according to claim 1, characterized in that: The alkaline salt is potassium tert-butoxide or potassium carbonate.
3. The method for preparing an amine-substituted phenanthridine compound according to claim 1, characterized in that: The amine compounds are melatonin, D-amino acid oxidase inhibitors, fludioxonil, indazole, benzimidazole, benzimorpholine, carbazole and its substituted derivatives, and 2-[2-(1-piperazinyl)ethoxy]ethanol.
4. The method for preparing an amine-substituted phenanthridine compound according to claim 1, characterized in that: The organic solvent it belongs to is N,N-dimethylformamide.
5. The method for preparing an amine-substituted phenanthrene compound according to claim 1, characterized in that, The amine-substituted phenanthridine compound has any of the following structural formulas:
6. The method for preparing an amine-substituted phenanthridine compound according to claim 1, characterized in that: The molar ratio of compound (I), basic salt and amine compound is 1:1 to 2:1 to 2.
7. A method for preparing an amine-substituted phenanthridine compound according to any one of claims 1 to 6, characterized in that: The structural formula of compound (I) is The basic salt is potassium carbonate, the amine compound is 2-[2-(1-piperazinyl)ethoxy]ethanol, and the structural formula of the amine-substituted phenanthridine compound is [structure missing].
8. The method for preparing an amine-substituted phenanthridine compound according to claim 7, characterized in that: The amine-substituted phenanthridine compound was added to an organic solvent and reacted with fumaric acid under reflux at 80°C to obtain the product.
9. The application of an amine-substituted phenanthridine compound according to claim 8, characterized in that: The product obtained by reflux heating was recrystallized from petroleum ether (PE) and methanol to obtain the final product.
10. A method for preparing an amine-substituted phenanthrene compound according to any one of claims 1 to 6, characterized in that: The structural formula of compound (I) is The basic salt is potassium tert-butoxide, and the amine compounds are melatonin, D-amino acid oxidase inhibitors, fludioxonil, indazole, benzimidazole, benzimorpholine or carbazole and their substitutes.
Citation Information
Patent Citations
Method for preparing pharmaceutical pure quetiapine fumarate
CN101190902A
Process for preparing quetiapine fumarate
CN101198599A
Quetiapine synthesizing method
CN105859653A
Efficient preparation method of quetiapine fumarate
CN114181172A
Deuterium-labeled quetiapine fumarate isotope compound as well as preparation method and food detection method thereof
CN120136813A
